Provided by Tiger Fintech (Singapore) Pte. Ltd.

Viking Therapeutics

23.72
-0.2200-0.92%
Post-market: 23.65-0.0700-0.30%19:51 EDT
Volume:2.72M
Turnover:65.23M
Market Cap:2.66B
PE:-23.52
High:24.68
Open:23.83
Low:23.30
Close:23.94
Loading ...

Viking Therapeutics’ VK2735 Gains Buy Rating Amid Pfizer’s GLP-1 Drug Halt and Promising Trial Results

TIPRANKS
·
15 Apr

Pfizer's $130B Weight-Loss Dream Just Collapsed

GuruFocus.com
·
14 Apr

BTIG highlights some reasons to own Viking shares after danuglipron discontinued

TIPRANKS
·
14 Apr

Pfizer just had a big setback in its race for an Ozempic competitor

Quartz
·
14 Apr

Smaller obesity drugmakers jump after Pfizer scraps weight-loss pill

TIPRANKS
·
14 Apr

Viking Seen as Potential Ticket To Get Pfizer Back Into Obesity Game -- Market Talk

Dow Jones
·
14 Apr

US STOCKS-Tech stocks power Wall St higher after Trump's tariff relief for some electronics

Reuters
·
14 Apr

Viking, Structure rally after Pfizer halts obesity drug development

TIPRANKS
·
14 Apr

Obesity Drugmakers Shares Rise After Pfizer Ends Development of Weight-Loss Pill Danuglipron

Reuters
·
14 Apr

Shares of Eli Lilly up 1.8%, Drug Developer Viking Therapeutics Shares Rise 13%

THOMSON REUTERS
·
14 Apr

Shares of U.S. Listed Obesity Drugmakers Rise After Pfizer to End Development of Its Experimental Weight-Loss Pill

THOMSON REUTERS
·
14 Apr

BUZZ-U.S. STOCKS ON THE MOVE-Goldman Sachs, Pfizer, Best Buy

Reuters
·
14 Apr

BUZZ-Obesity drugmakers rise after Pfizer ends development of weight-loss pill

Reuters
·
14 Apr

Shares of Eli Lilly up 2%, Drug Developer Viking Therapeutics Shares Rise 16.5%

THOMSON REUTERS
·
14 Apr

Shares of U.S. Listed Obesity Drugmakers Rise Premarket After Pfizer to End Development of Its Experimental Weight-Loss Pill

THOMSON REUTERS
·
14 Apr

Will Viking Therapeutics Be a Top Healthcare Stock in 10 Years?

Motley Fool
·
10 Apr

Viking Therapeutics Initiated at Neutral by Goldman Sachs

Dow Jones
·
09 Apr

LLY vs. NVO: Which Weight-Loss Drug Stock is a Stronger Play Now?

Zacks
·
08 Apr

Goldman Sachs Initiates Viking Therapeutics With Neutral Rating, $30 Price Target

MT Newswires Live
·
08 Apr

Viking Therapeutics initiated with a Neutral at Goldman Sachs

TIPRANKS
·
08 Apr